Acute non-lymphocytic leukaemia and myelofibrosis following sequential hemibody irradiation for prostatic carcinoma.
Sequential hemibody radiotherapy (SHBI) is currently being evaluated in clinical trials as adjuvant treatment in cancer patients who are potential long-term survivors. The potential late adverse effects of this therapeutic modality on the bone marrow may place patients at risk for the complications of aplasia, leukaemia, and myeloproliferative syndromes. We describe a case of acute non-lymphocytic leukaemia and myelofibrosis following SHBI for prostate carcinoma. The possible role of radiation in the induction of these abnormalities is discussed.
Chin-Yee
I
I
Department of Hematology/Blood Bank, Victoria Hospital Corporation, London, Ontario, Canada.
Porter
A T
AT
Lohmann
R C
RC
D000230:Adenocarcinoma / Q000532:radiotherapy*; D000368:Aged; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology*; D007953:Leukemia, Radiation-Induced / Q000209:etiology*; D008297:Male; D055728:Primary Myelofibrosis / Q000209:etiology*; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects* / Q000379:methods; D011879:Radiotherapy Dosage